Pharmacotherapy for obesity.

Abstract:

:Pharmacotherapy for the management of obesity is primarily aimed at weight loss, weight loss maintenance and risk reduction, and has included thyroid hormone, amphetamines, phentermine, amfepramone (diethylpropion), phenylpropanolamine, mazindol, fenfluramines and, more recently, sibutramine and orlistat. These agents decrease appetite, reduce absorption of fat or increase energy expenditure. Primary endpoints used to evaluate anti-obesity drugs most frequently include mean weight loss, percentage weight loss and proportion of patients losing >or=5% and >or=10% of initial bodyweight. Secondary endpoints may include reduction in body fat, risk factors for cardiovascular disease and the incidences of diseases such as diabetes mellitus. Most pharmacotherapies have demonstrated significantly greater weight loss in patients on active treatment than those receiving placebo in short-term (or=10% loss of initial bodyweight in 46% of patients. For patients taking orlistat, weight loss was 2.2 kg greater than those on placebo at 4 years (p<0.001), with significantly more patients achieving >or=10% loss of initial bodyweight (26.2% and 15.6%, respectively; p<0.001). Other drugs that have been evaluated for weight loss include ephedrine, the antidepressants fluoxetine and bupropion, and the antiepileptics topiramate and zonisamide. Two clinical trials with fluoxetine both reported no significant difference in weight loss compared with placebo at 52 weeks. Clinical trials evaluating ephedrine, bupropion, topiramate and zonisamide have demonstrated significantly greater weight loss than placebo but have been limited to 16-26 weeks' treatment. A major obstacle to the evaluation of the clinical trials is the potential bias resulting from low study completion rates. Completion rates varied from 52.8% of phentermine recipients in a 9-month study, to 40% of fenfluramine recipients in a 24-week comparative study with phentermine and 18% of amfepramone recipients in a 24-week study. One-year completion rates range from 51% to 73% for sibutramine and from 66% to 85% for orlistat. Other potential sources of bias include run-in periods and subsequent patient selection based on compliance or initial weight loss. Several potential new therapies targeting weight loss and obesity through the CNS pathways or peripheral adiposity signals are in early phase clinical trials. Over the next decade the drug treatment of obesity is likely to change significantly because of the availability of new pharmacotherapies to regulate eating behaviours, nutrient partitioning and/or energy expenditure.

journal_name

Drugs

journal_title

Drugs

authors

Ioannides-Demos LL,Proietto J,McNeil JJ

doi

10.2165/00003495-200565100-00006

subject

Has Abstract

pub_date

2005-01-01 00:00:00

pages

1391-418

issue

10

eissn

0012-6667

issn

1179-1950

pii

65106

journal_volume

65

pub_type

杂志文章,meta分析,评审

相关文献

DRUGS文献大全
  • The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

    abstract::The endothelin family of peptides are extremely potent endogenous vasoconstrictor and pressor agents. Of the 3 isoforms, endothelin-1 is the major isoform produced by the vascular endothelium and is, therefore, likely to be of most importance for regulation of vascular function. Two endothelin receptor subtypes have s...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199651010-00003

    authors: Ferro CJ,Webb DJ

    更新日期:1996-01-01 00:00:00

  • Drugs and receptors. An overview of the current state of knowledge.

    abstract::This paper reviews the theoretical concepts and methods utilised with isolated tissues to characterise drugs and drug receptors. Specifically the impact, on the in vitro measurement of agonist affinity and relative efficacy, of the idea that receptors bind to transduction proteins in the lipid bilayer of the cell memb...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199040050-00003

    authors: Kenakin T

    更新日期:1990-11-01 00:00:00

  • Pharmacological interventions for the induction of ovulation.

    abstract::Ovulation induction is the most common medical intervention for the treatment of infertility. Clomifene is generally the first treatment choice for patients with amenorrhoea, unless there is profound hypothalamic deficiency. When clomifene fails to induce ovulation, menotropins (human menopausal gonadotrophin) or gona...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199550030-00006

    authors: Collins JA,Hughes EG

    更新日期:1995-09-01 00:00:00

  • Low molecular weight heparins: a guide to their optimum use in pregnancy.

    abstract::The incidence of pulmonary embolism (PE) and venous thromboembolism (VTE) is higher in pregnant patients than in non-pregnant patients. The incidence of thrombosis in all pregnancies is reported to be between 0.05 and 1%, and an incidence as high as 3% may be present in women after caesarean section. Anticoagulant med...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262030-00004

    authors: Laurent P,Dussarat GV,Bonal J,Jego C,Talard P,Bouchiat C,Cellarier G

    更新日期:2002-01-01 00:00:00

  • Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis.

    abstract::Budesonide MMX(®) (Cortiment(®); Uceris(®)) is a novel once-daily oral formulation of budesonide using Multi Matrix (MMX(®)) colonic delivery technology to permit the release of budesonide at a controlled rate throughout the colon. It is available in the USA for the induction of remission in patients with active, mild...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0396-8

    authors: Hoy SM

    更新日期:2015-05-01 00:00:00

  • Drugs in the treatment of female infertility. Recent advances.

    abstract::Involuntary infertility is an increasing problem in this era of delayed childbearing. Fortunately, many advances have been made recently in the medical and surgical treatment of infertility. This article reviews the principal aetiologies of infertility and their treatments, and focuses on the current and future uses o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198632020-00004

    authors: Quigley MM

    更新日期:1986-08-01 00:00:00

  • Induction therapy in renal transplant recipients: how convincing is the current evidence?

    abstract::The goal of organ transplantation is to provide durable organ function while minimizing risks such as infection and cancer. Induction therapy in renal transplantation provides improved short- and long-term graft outcomes compared with placebo. Three agents are currently available and widely used in the US; rabbit anti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11631300-000000000-00000

    authors: Wagner SJ,Brennan DC

    更新日期:2012-03-26 00:00:00

  • Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice.

    abstract::Cisatracurium besilate (besylate) is a nondepolarising neuromuscular blocking agent with an intermediate duration of action. It is the R-cis, R'-cis isomer of atracurium besilate and is approximately 3-fold more potent than the mixture of isomers that constitute the parent drug. The ED95 for cisatracurium besilate (do...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199753050-00012

    authors: Bryson HM,Faulds D

    更新日期:1997-05-01 00:00:00

  • Correction to: Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.

    abstract::The original article can be found online. ...

    journal_title:Drugs

    pub_type: 已发布勘误

    doi:10.1007/s40265-020-01407-8

    authors: Scott LJ

    更新日期:2020-09-01 00:00:00

  • Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

    abstract::Part I of this article reviewed the targets against which anti-HIV drugs can be directed, problems in assessing active compounds (e.g. resistance development and use of surrogate end-points). and nucleoside analogues effective against HIV reverse transcriptase. Intensive research is currently being undertaken in labor...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199345050-00002

    authors: Sandström E,Oberg B

    更新日期:1993-05-01 00:00:00

  • [Pain management: health economics and quality of life considerations].

    abstract::Pain represents a major clinical, social and economic problem, with estimates of its prevalence ranging from 8% to more than 60%, depending on the population. The impact of pain on economies is enormous, with the cost of back pain alone equivalent to more than one-fifth of one country's total health expenditure and 1....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Phillips CJ

    更新日期:2003-01-01 00:00:00

  • Current status of dopamine agonists in Parkinson's disease management.

    abstract::The occurrence of late side effects of long term levodopa therapy (fluctuations in motor performance, abnormal movements, and symptoms unresponsive to dihydroxyphenylalanine) led to the search for novel anti-Parkinsonian drugs. Dopamine agonists are one of the newer families of anti-Parkinsonian agents, and they inclu...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199346030-00005

    authors: Montastruc JL,Rascol O,Senard JM

    更新日期:1993-09-01 00:00:00

  • Pharmacological management of first-episode schizophrenia and related nonaffective psychoses.

    abstract::Schizophrenia is a severe mental illness characterised by abnormalities of thought and perception that affects 1-2% of the population. Patients who experience a first episode of schizophrenia should be treated early and optimally with antipsychotic agents to lessen the morbidity of the initial episode and possibly imp...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363210-00001

    authors: Bradford DW,Perkins DO,Lieberman JA

    更新日期:2003-01-01 00:00:00

  • Antidiabetic drugs present and future: will improving insulin resistance benefit cardiovascular risk in type 2 diabetes mellitus?

    abstract::Results from the United Kingdom Prospective Diabetes Study showed that intensive treatment of type 2 (non-insulin-dependent) diabetes mellitus, with sulphonylureas or insulin, significantly reduced microvascular complications but did not have a significant effect on macrovascular complications after 10 years. Insulin ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060050-00004

    authors: Campbell IW

    更新日期:2000-11-01 00:00:00

  • In vitro activity of desacetylcefotaxime and the interaction with its parent compound, cefotaxime.

    abstract::Antibacterial activities of cefotaxime and its major metabolite, desacetylcefotaxime, against 178 strains (of 10 species) were assessed in terms of minimum inhibitory concentrations (MIC50 and MIC80), and were compared with those of cefoperazone and ceftazidime. The activity of desacetylcefotaxime was several times le...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198800352-00013

    authors: Oizumi K,Hayashi I,Aonuma S,Konno K

    更新日期:1988-01-01 00:00:00

  • Fenfluramine: a review of its pharmacological properties and therapeutic efficacy in obesity.

    abstract::Fenfluramine has been used for a number of years as a short-term adjunct to diet in the management of obesity. Controlled studies and clinical experience have shown that it possesses anorectic activity at least as good as that of other therapeutically useful drugs of its type, but like these drugs it has only a limite...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197510040-00001

    authors: Pinder RM,Brogden RN,Sawyer PR,Speight TM,Avery GS

    更新日期:1975-01-01 00:00:00

  • Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis.

    abstract::Levocabastine is a potent and selective histamine H1-receptor antagonist which has been evaluated as a topical treatment (nasal spray and/or eyedrops) for allergic rhinitis and/or conjunctivitis. Data available at the time of the previous review in Drugs, together with more recent results, have clearly demonstrated th...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199550060-00009

    authors: Noble S,McTavish D

    更新日期:1995-12-01 00:00:00

  • Susoctocog Alfa: A Review in Acquired Haemophilia A.

    abstract::Intravenous susoctocog alfa (Obizur(®)) is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). Intravenous susoctocog alfa was an effective and generally well to...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0576-1

    authors: Burness CB,Scott LJ

    更新日期:2016-05-01 00:00:00

  • Emerging options in the treatment of bipolar disorders.

    abstract::Bipolar disorder is a common and severe condition, and has a clinical outcome that is frequently sub-optimal. Only a small number of therapeutic options are currently available for the disorder. A growing range of novel therapeutic options for the treatment of bipolar disorder are under investigation. These include th...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161100-00004

    authors: Berk M,Segal J,Janet L,Vorster M

    更新日期:2001-01-01 00:00:00

  • Endothelial function. General considerations.

    abstract::The endothelium is involved in both the physiological regulation of vascular tone and the structural transformation of the vessel under pathological conditions. Under physiological conditions, endothelial cells continuously secrete nitric oxide (NO), which relaxes smooth muscle cells and ensures vessel patency. Damage...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199700531-00003

    authors: Haller H

    更新日期:1997-01-01 00:00:00

  • Are there potential non-lipid-lowering uses of statins?

    abstract::Recent clinical trials have demonstrated beyond doubt that statins are effective in the prevention of acute coronary events. Critical analysis of these studies suggests that the benefits of statin therapy cannot be fully explained on the basis of reductions in plasma cholesterol levels. Accumulating knowledge of the a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856040-00001

    authors: Wheeler DC

    更新日期:1998-10-01 00:00:00

  • Canagliflozin: first global approval.

    abstract::Canagliflozin (Invokana™), an oral selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, is under global development with Mitsubishi Tanabe Pharma and Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson, for the treatment of type 2 diabetes mellitus. SGLT2 are mainly located in the proximal tubule of t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0064-9

    authors: Elkinson S,Scott LJ

    更新日期:2013-06-01 00:00:00

  • Clinical aspects of invasive candidiasis in critically ill patients.

    abstract::Invasive candidiasis has emerged as an important cause of morbidity and mortality in intensive care unit patients. This short review focuses on many aspects of Candida infection in critically ill patients including epidemiology, impact on mortality, problems related to diagnosis, strategies to identify patients at ris...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11315590-000000000-00000

    authors: Pennisi M,Antonelli M

    更新日期:2009-01-01 00:00:00

  • Drug treatment of hypertension.

    abstract::There are several first choices for the treatment of mild and moderate hypertension. The selection of a drug may be influenced by concomitant pathology, with positive indications for particular drugs, e.g. coexistent angina, indicating use of a beta-receptor blocking drug or calcium antagonist; fluid retention indicat...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198800356-00006

    authors: Prichard BN

    更新日期:1988-01-01 00:00:00

  • Vitamin A acid: a review of its pharmacological properties and therapeutic use in the topical treatment of acne vulgaris.

    abstract::Vitamin A acid (retinoic acid: tretinoin) is a vitamin A derivative used in the topical treatment of acne. It acts by 'unseating' comedones, improvement developing slowly over a period of 2 to 3 or more months, and is also said to prevent the formation of new lesions. About three-quarters of patients with acne vulgari...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197714060-00001

    authors: Heel RC,Brogden RN,Speight TM,Avery GS

    更新日期:1977-12-01 00:00:00

  • Treatment options for sleep apnoea.

    abstract::Sleep apnoea (SA) is a common sleep disorder affecting 4 to 25% of the adult population. The most common form, obstructive SA, is characterised by recurrent upper airway obstruction during sleep associated with sleep disruption and hypoxaemia. There is increasing evidence that SA leads to impaired vigilance, quality o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161020-00007

    authors: Grunstein RR,Hedner J,Grote L

    更新日期:2001-01-01 00:00:00

  • Oxantel-pyrantel in various regimens for the treatment of soil transmitted helminthiasis in rural and urban communities.

    abstract::204 individuals from a rural community were given a single dose of oxantel-pyrantel at 15mg/kg bodyweight and if still infected, 20mg/kg bodyweight, with cure rates of 100%, 53% and 71% for ascariasis, trichuriasis and hookworm infection, respectively. From an urban community, 124 patients were given the same drug eit...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-197800151-00016

    authors: Cabrera BD,Sy FS

    更新日期:1978-01-01 00:00:00

  • Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.

    abstract::Empagliflozin/linagliptin (Glyxambi(®)) is a once-daily sodium glucose co-transporter type 2 (SGLT2) inhibitor and dipeptidyl peptidase (DPP)-4 inhibitor fixed-dose combination product that is approved in the USA as an adjunct to diet and exercise in adults with type 2 diabetes (T2D) when treatment with both empaglifl...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0457-z

    authors: Kim ES,Deeks ED

    更新日期:2015-09-01 00:00:00

  • Clascoterone: First Approval.

    abstract::Clascoterone (Winlevi®) is an androgen receptor inhibitor being developed as a topical cream and solution by Cassiopea (a spin-out company of Cosmo Pharmaceuticals) for the treatment of androgen-dependent skin disorders, including androgenetic alopecia and acne vulgaris. Although the exact mechanism of action of clasc...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01417-6

    authors: Dhillon S

    更新日期:2020-11-01 00:00:00

  • Early intervention in multiple sclerosis : better outcomes for patients and society?

    abstract::Multiple sclerosis (MS) is thought to be a chronic inflammatory disorder of the CNS. The past decade has seen the introduction of the new immunomodulatory drugs, interferon (IFN)-beta and glatiramer acetate, that have considerably improved the therapeutic options for this often disabling disease. The efficacy of these...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363150-00001

    authors: Flachenecker P,Rieckmann P

    更新日期:2003-01-01 00:00:00